Inside Switzerland's Cannabis Pilot Sales Trials

September 27, 2026

Photo by Austin Loveing via Unsplash.

Walk into a pharmacy in Zurich's Kreis 4 district and, alongside the blood pressure cuffs and cough syrup, you can pick up cannabis flower grown to Swiss organic standards, provided you're enrolled in Zuri Can and show your participant card. This isn't legalization in the way Canada or Uruguay did it, with retail shelves open to any adult who walks in off the street. Switzerland is running something narrower and slower: a set of federally sanctioned scientific trials, embedded in real pharmacies and social clubs across seven cities, where every gram sold gets logged against a participant's health data.

As of mid-2025, roughly 10,400 adults are enrolled across those seven projects -- a sliver of the estimated 220,000 people in Switzerland who report using cannabis monthly, but a sliver that's generating the kind of granular, longitudinal data that a simple legalize-and-see approach never would. Every trial operates under a specific 2021 legal provision, Article 8a of the Betäubungsmittelgesetz (BetmG), which permits time-limited studies rather than a change in national policy. Nothing about it is a free-for-all -- the Federal Office of Public Health signs off on each project and tracks outcomes continuously.

Now an eighth trial is about to launch in St. Gallen, and it's testing something none of the earlier seven have touched: delivering regulated cannabis straight to people's homes.

The Legal Mechanism: Article 8a and Why Switzerland Chose Trials Over Legalization

Photo by Christian Wasserfallen via Pexels.

Article 8a BetmG didn't appear out of nowhere -- Parliament added it to the existing narcotics law in 2020 specifically to create a legal pathway for scientific studies on regulated cannabis distribution to adults, without touching the underlying prohibition that still governs the rest of the country. That distinction matters. Switzerland hasn't decided cannabis is legal; it has decided it's worth finding out, under controlled conditions, what happens when adults can buy it through a regulated channel instead of the illicit market.

The Federal Office of Public Health, known domestically as BAG (or OFSP in French-speaking cantons), sits at the center of every one of these projects. No trial gets off the ground without FOPH approval, and approval hinges on a detailed youth- and health-protection concept -- rules covering age verification, THC potency limits, purchase caps, and mandatory counseling touchpoints for participants. Cities and universities design the operational side, but FOPH sets the guardrails and requires ongoing reporting on health outcomes, consumption patterns and any adverse effects.

The logic behind choosing trials over outright legalization is fairly explicit in Swiss policy circles: rather than legislate first and study the fallout later, the country wanted usable evidence before committing to anything at the federal level. That means data on whether regulated access changes how much people use, whether it reduces black-market purchasing, and whether health indicators like sleep, anxiety and problematic-use patterns move in a measurable direction. It's a slower path than legalization by referendum, but it produces a paper trail policymakers can actually point to.

By a February 2026 FOPH update, seven trials were active nationwide, with an eighth -- St. Gallen's CanLeg project -- cleared and about to launch. That steady, incremental expansion is itself part of the design: each new pilot tests a slightly different distribution model or population, adding to a growing dataset rather than replacing the experiment that came before it.

Where the Trials Are Running

Photo by cottonbro studio via Pexels.

The seven trials running as of June 2025 are spread across a mix of major cities and smaller municipalities: Basel-Stadt, Bern, Biel, Lausanne, Lucerne, Vernier, and Zurich, along with additional municipalities within canton Zurich and canton Basel-Landschaft. That geographic spread wasn't accidental -- it lets researchers compare outcomes across German-speaking and French-speaking regions, and across cities of very different sizes and drug-policy histories.

Combined, these projects had enrolled about 10,400 adults by mid-2025. Set against Switzerland's estimated 220,000 monthly cannabis users in 2022, that's roughly five percent of the country's regular user population -- small enough to stay scientifically manageable, large enough to generate statistically meaningful health and consumption data over a multi-year period.

What's notable is that no two trials look quite alike. Each city built its own distribution model within the same Article 8a framework, which means researchers aren't just testing whether regulated cannabis access works -- they're testing which version of it works best. Some cities lean heavily on pharmacies as the point of sale, treating cannabis distribution as an extension of existing healthcare infrastructure. Others have built dedicated social clubs, member-based spaces closer to the Spanish cannabis club model, where participants pick up product and can also access counseling or harm-reduction resources on-site. That variation is deliberate -- it's the closest thing Switzerland has to running parallel policy experiments simultaneously.

The newest addition changes the scale of the whole undertaking. On June 16, 2026, the Swiss Cannabis Research Association announced CanLeg, a canton-wide trial in St. Gallen that will become the eighth pilot and, by participant count, the largest single new project added to the program. Unlike the city-specific trials that came before it, CanLeg is designed at the canton level from the outset -- a sign that Switzerland's pilot approach is starting to scale up rather than simply multiply.

Zurich's Zuri Can: The Largest Experiment

Photo by Terrance Barksdale via Pexels.

Zuri Can, launched in 2023 as a joint project between the city of Zurich and the University of Zurich, is the biggest and most closely watched of the seven original trials. It runs through 20 outlets: ten pharmacies scattered across the city, the municipal drug information center, and nine dedicated social clubs. That spread gives researchers a direct comparison between medicalized, pharmacy-based access and a more community-oriented club model, all within a single city and under one set of health-protection rules.

Product sold through Zuri Can is cannabis flower and resin grown to Swiss organic standards, with clearly defined THC and CBD levels printed on packaging -- a level of labeling precision that's simply unavailable on the illicit market participants would otherwise be buying from. Every purchase ties back to a participant profile, letting the university team track consumption over time rather than relying on self-reported surveys alone.

The project was originally slated to wrap up in October 2026, but as of mid-April 2026 the city and university extended it by two years, pushing the end date to 2028. That extension is itself a data point -- it suggests the early results were promising enough, or the dataset valuable enough, that cutting the trial off on schedule would have meant losing momentum right as longer-term outcomes started to emerge.

Those city-reported outcomes are the real headline. Participants have shown less problematic use over time, fewer reported sleep disturbances, fewer anxiety symptoms, and a measurable drop in doctor visits related to cannabis use. None of that proves regulated access is a health intervention in the clinical sense, but it's a meaningfully different pattern than what critics of cannabis pilots typically predict, and it's exactly the kind of outcome data Article 8a was designed to surface before any national law gets written.

Lausanne's Cann-L and the Question of Reduced Use

Photo by Thought Catalog via Unsplash.

Lausanne's Cann-L trial opened in December 2023, roughly a year after Zuri Can, and has grown into the second-largest of the pilot projects by enrollment. By the end of April 2026, it had more than 1,750 registered adults, with an average age around 36 and a participant base that skews heavily male, at roughly 75 percent.

What sets Cann-L apart isn't just its size -- it's a follow-up study the project ran on its first cohort of 670 participants, all of whom had been enrolled for at least 18 months. That follow-up found an average 20 percent reduction in cannabis consumption among those long-enrolled participants, a figure that runs counter to a common assumption about regulated access: that making a substance easier and safer to obtain will simply drive people to use more of it.

Cann-L's structure offers a plausible explanation. Enrollment comes paired with counseling support, and participants have regular contact points with staff who can flag concerning use patterns early. If access is framed less as a retail transaction and more as a supervised program with a health-support layer attached, it's not unreasonable that some participants end up moderating their use rather than escalating it -- particularly if part of what drove heavier use before enrollment was inconsistent product quality or the unpredictability of buying from an illicit source.

It's worth being careful about how far to extend that finding. This is one cohort, in one city, drawn from people who volunteered for a research program in the first place -- a group that may already be more motivated toward moderation than the general population of cannabis users. But it's still the clearest quantitative signal so far, from any of the seven trials, that regulated access under a counseling model doesn't automatically translate into higher consumption. That's precisely the sort of finding federal lawmakers will want in hand before deciding how a national law should be structured.

St. Gallen's CanLeg: Testing Home Delivery for the First Time

Photo by Vitaly Gariev via Unsplash.

St. Gallen's CanLeg, announced by the Swiss Cannabis Research Association on June 16, 2026, is built differently from anything that came before it. It's designed to run for five years and enroll 5,000 participants -- making it, by both duration and scale, the most ambitious single trial in the program so far.

The structural innovation is in how participants are split. Rather than testing one distribution model, CanLeg divides its enrollees into three groups: one that purchases through pharmacies, mirroring the model most of the existing trials already use; one that receives cannabis via home delivery; and a control group used as a comparison baseline. That three-way split lets researchers isolate the effect of the access method itself, rather than just measuring outcomes for whichever single model a given city happened to build.

The home-delivery arm is the genuinely new piece. None of the seven earlier pilots -- not Zuri Can, not Cann-L, not the smaller projects in Basel-Stadt, Bern, Biel, Lucerne or Vernier -- have tested delivering regulated cannabis directly to a participant's door. It's a meaningful departure, because delivery removes the in-person checkpoint that pharmacies and social clubs naturally provide, raising questions about age verification, purchase-limit enforcement, and whether the counseling contact built into models like Cann-L can survive a transaction that never puts a participant face-to-face with staff.

CanLeg's design suggests St. Gallen's researchers see that as worth testing head-on rather than avoiding. If home delivery performs comparably to pharmacy pickup on health and consumption metrics, it becomes a strong candidate for how a future national framework handles distribution in rural cantons where a dedicated pharmacy or social club simply isn't practical. If it doesn't, that's useful information too -- and either way, it's the kind of direct model-versus-model comparison the earlier single-method trials couldn't produce on their own.

The National Law Stuck Behind the Pilots

In the cantonal consultation on the draft cannabis law, more cantons opposed or leaned against the proposal (15) than supported it (10), with only one canton remaining neutral.

While the pilots keep running, the actual national cannabis law they're meant to inform is stalled in committee. The parliamentary health committee, SGK-N, has been drafting a federal Cannabisproduktegesetz to implement the Siegenthaler initiative, the parliamentary motion that originally pushed Switzerland toward a regulated-market approach. Getting that bill through consultation, though, has been anything but smooth.

The consultation process drew 162 responses. Of those, only 10 cantons came out supportive; 15 were opposed or leaning against; one stayed neutral. That's a lopsided result for a federal drug-policy bill in a country where cantonal buy-in typically matters as much as the vote in Bern itself.

The committee pushed forward anyway, at least for now. On May 6-8, 2026, SGK-N voted 16-8 to keep working on the bill, and separately rejected, by 17-8, a motion to suspend the whole effort. So the legislation is alive, but only barely, and the vote margins make clear it's not a settled question within the committee itself.

The cantonal opposition is specific, not abstract. Zurich, Bern, Aargau and Thurgau all rejected the draft, citing what they describe as excessive regulation and an administrative burden they're not equipped to absorb. Several of these same cantons are running or hosting the pilot trials themselves, and their position is essentially: show us what the data says before you write it into permanent law. That's the leverage the pilots have created -- cantons can point to Zuri Can's extension or Cann-L's consumption findings and argue the federal bill is getting ahead of the evidence.

A Federal Council report to Parliament is expected in summer 2026, with floor debate starting that fall. Given the pace so far, and the size of the gap between supportive and opposed cantons, that debate could easily stretch past the October 2027 federal elections -- meaning Switzerland may enter a new legislative session still without a finished cannabis law, pilots and all.

None of this is a backdoor into legalization moving at a discreet pace -- it's deliberately slow science, and the cantons blocking the federal bill are using that slowness as their explicit argument. Zurich, Bern, Aargau and Thurgau aren't rejecting regulated cannabis on principle; they're rejecting a law written before the pilots they're hosting have finished producing results. That's a genuinely different posture than blanket opposition, and it puts real pressure on Bern to let the data finish accumulating before locking in a national framework.

The shape of that eventual debate is already becoming visible in what the pilots are producing. Lausanne's 20 percent consumption drop among long-enrolled Cann-L participants undercuts the assumption that easier access simply means more use. St. Gallen's CanLeg, with its head-to-head test of pharmacy pickup against home delivery, is going to answer a question no city trial has even attempted: whether removing the in-person checkpoint changes outcomes at all. Increasingly, the live question in Swiss cannabis policy isn't whether to regulate -- it's which delivery model, which counseling structure, which THC ceiling actually produces the outcomes Zurich and Lausanne have started to document.

For now, though, none of that changes the practical reality on the ground. With SGK-N's committee votes this narrow and a Federal Council report still months from arriving, floor debate realistically bleeds past the October 2027 elections, and a national Cannabisproduktegesetz could remain unwritten for years yet. Until it lands, the roughly 10,400 people enrolled in Zuri Can, Cann-L, and the other pilots -- soon joined by CanLeg's 5,000 -- are, quite literally, the only adults in Switzerland for whom buying regulated cannabis is legal at all.